Key result
Aspirin resistance was significantly more prevalent in patients with STEMI (50%) and UA/NSTEMI (35.8%) compared to those with stable angina (19.6%) or ruled-out ACS (17.2%) (P<0.001).
Why the study?
Is biochemical aspirin resistance associated with acute coronary syndromes in patients presenting with chest pain on aspirin therapy?
Observational (n=338)
Is biochemical aspirin resistance associated with acute coronary syndromes in patients presenting with chest pain on aspirin therapy?
p-value: p=<.001
Biochemical aspirin resistance is significantly more prevalent in patients presenting with acute coronary syndromes, particularly STEMI, compared to those with stable angina or non-cardiac chest pain.
No takes yet. Share an insight, caveat, or question.
Aspirin resistance was associated with ACS; hypothesis-generating for testing or therapy adjustment and should not yet change practice.
Aydınalp et al. (2010) conducted an observational in Chest pain (n=338). Acute coronary syndromes (ACS) vs. Stable angina pectoris or ruled-out ACS was evaluated on Prevalence of aspirin resistance (p=<.001). Aspirin resistance was significantly more prevalent in patients with STEMI (50%) and UA/NSTEMI (35.8%) compared to those with stable angina (19.6%) or ruled-out ACS (17.2%) (P<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: